BOLT
Bolt Biotherapeutics
NASDAQ: BOLT · HEALTHCARE · BIOTECHNOLOGY
$4.87
+2.21% today
Updated 2026-04-30
Market cap
$9.28M
P/E ratio
—
P/S ratio
1.21x
EPS (TTM)
$-17.85
Dividend yield
—
52W range
$4 – $9
Volume
0.0M
Bolt Biotherapeutics (BOLT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-224.20%
ROE
-79.70%
ROA
-27.70%
Debt/equity
0.73x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $0.00 | $-11.59M | — | — | — |
| 2019 | $215000.00 | $-30.49M | 100.00% | -14,404.19% | -14,180.00% |
| 2020 | $231000.00 | $-60.73M | -17,370.56% | -21,290.91% | -26,289.18% |
| 2021 | $1.26M | $-98.59M | -5,904.37% | -7,364.13% | -7,824.68% |
| 2022 | $5.73M | $-88.10M | -1,176.37% | -1,576.56% | -1,537.76% |
| 2023 | $7.88M | $-69.20M | -681.39% | -967.45% | -878.58% |
| 2024 | $7.69M | $-63.12M | 100.00% | -949.91% | -820.78% |
| 2025 | $7.70M | $-33.38M | 80.62% | -450.07% | -433.74% |